CGIM
TEVA icon

Capital Group Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Capital Group Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,651
Closed -$109K – 200
2023
Q3 		$109K Hold
10,651
– – 0.01% 198
2023
Q2 		$80.2K Sell
10,651
-77,570
-88% -$629K ﹤0.01% 200
2023
Q1 		$781K Sell
88,221
-8,745
-9% -$86.5K 0.04% 163
2022
Q4 		$884K Buy
+96,966
New +$846K 0.03% 160

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Capital Group Investment Management's TEVA Position: Q4 2023 in Review

Capital Group Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2023, closing a stake of 10,651 shares — an estimated $109K sold.

Capital Group Investment Management first reported a position in TEVA in Q4 2022 and held it in 4 quarters. The position peaked at $884K in Q4 2022. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

  • Capital Group Investment Management reported no remaining Teva Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Capital Group Investment Management sold 10,651 Teva Pharmaceuticals shares in Q4 2023, an estimated $109K.
  • Capital Group Investment Management first reported a position in Teva Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Capital Group Investment Management's Teva Pharmaceuticals position peaked at $884K in Q4 2022.
  • 447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on Capital Group Investment Management's 13F filing for Q4 2023, filed 13 Feb 2024.